Notice Regarding Section 602 of the Veterans Health Care Act of 1992; Contract Pharmacy Services

Federal RegisterAug 23, 1996

Ask Donna

What actually matters in this document.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

RIN 0905-ZA96

Notice Regarding Section 602 of the Veterans Health Care Act of

1992; Contract Pharmacy Services

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Final notice.

-----------------------------------------------------------------------

SUMMARY: Section 602 of Public Law 102-585, the ``Veterans Health Care

Act of 1992'' (the ``Act''), enacted section 340B of the Public Health

Service Act (``PHS Act''), ``Limitation on Prices of Drugs Purchased by

Covered Entities.'' Section 340B provides that a manufacturer who sells

covered outpatient drugs to eligible (covered) entities must sign a

pharmaceutical pricing agreement with the Secretary of Health and Human

Services (HHS) in which the manufacturer agrees to charge a price for

covered outpatient drugs that will not exceed an amount determined

under a statutory formula.

The purpose of this notice is to inform interested parties of final

guidelines regarding contract pharmacy services.

FOR FURTHER INFORMATION CONTACT: Annette Byrne, R. Ph., M.S., Director,

Drug Pricing Program, Bureau of Primary Health Care, Health Resources

and Services Administration, 4350 East West Highway, 10th Floor,

Bethesda, MD 20814, Phone (301) 594-4353, FAX (301) 594-4982.

EFFECTIVE DATE: August 23, 1996.

SUPPLEMENTARY INFORMATION:

(A) Background

Proposed guidelines for contract pharmacy services were announced

in the Federal Register at 60 FR 55586 on November 1, 1995. A comment

period of 30 days was established to allow interested parties to submit

comments. The Health Resources and Services Administration, Bureau of

Primary Health Care, acting through the Office of Drug Pricing (ODP),

received eleven letters including comments concerning the scope of the

340B Program, contractor certification, contractor and entity penalties

for drug diversion, creation of an agency relationship between the

entity and the contractor, entity responsibilities including price

establishment, reimbursement, inventory control, and the like.

Although some manufacturers expressed concerns regarding the

potential for drug diversion, the Department has received no evidence

of diversion that has required an official Departmental investigation.

This includes the various drug distribution systems, among them those

using contract pharmacy services. However, in response to

manufacturers' concerns, the Department intends to study the use of

contracted pharmacy services for accessing 340B drugs to determine if

there is evidence of drug diversion. In particular, the Department will

examine closely documented complaints, including the results of

manufacturers' audits, will use other analyses as deemed appropriate,

and will consider whether additional safeguards are necessary.

We received some very positive comments in support of the

mechanism. These comments discussed the many covered entities which do

not operate their own licensed pharmacies; therefore, the guidelines

encourage these entities to participate in the program. Because these

covered entities provide medical care for many individuals and families

with incomes well below 200% of the Federal poverty level and subsidize

prescription drugs for many of their patients, it was essential for

them to access 340B pricing. Covered entities could then use savings

realized from participation in the program to help subsidize

prescriptions for their lower income patients, increase the number of

patients whom they can subsidize and expand services and formularies.

One commenter described the guidelines as straightforward, clear and

consistent with section 340B. Another commenter stated that the ``use

of contract pharmacies by covered entities is fundamental to the

success of the VHCA [Veterans Health Care Act] drug pricing program.''

The commenter supported the guidelines and urged the Department to

expedite their completion, as the importance of the contract pharmacy

option to their members could not be overstated.

The following section presents a summary of all major comments,

grouped by subject, and a response to each comment. All comments were

considered in developing this final notice, with changes made to

increase clarity and readability. In addition, to provide further

technical assistance and guidance to covered entities interested in

using this mechanism, examples of report contents, a suggested system

to ensure an adequate drug tracking system, and a method to ensure

patient eligibility are included. Various commenters, and in particular

drug manufacturers, suggested the need for detailed systems. The

National Association of Community Health Centers suggested some of the

specific examples.

(B) Comments and Responses

(1) General

Comment: The use of contract pharmacy services is inconsistent with

section 340B of the PHS Act and results in an unauthorized expansion of

the program.

Response: Section 340B, which established the Drug Pricing Program,

requires manufacturers to sell to covered entities at or below a

ceiling price determined by a statutory formula. The statute is silent

as to permissible drug distribution systems. There is no requirement

for a covered entity to purchase drugs directly from the manufacturer

or to dispense drugs itself. It is clear that Congress envisioned that

various types of drug delivery systems would be used to meet the needs

of the very diversified group of 340B covered entities.

It has been the Department's position that if a covered entity

using contract pharmacy services requests to purchase a covered drug

from a participating manufacturer, the statute directs the manufacturer

to sell the drug at the discounted price. If the entity directs the

drug shipment to its contract pharmacy, we see no basis on which to

conclude that section 340B precludes this type of transaction or

otherwise

[[Page 43550]]

exempts the manufacturer from statutory compliance. However, the entity

must comply, under any distribution mechanism, with the statutory

prohibition on drug diversion.

During the early period of program implementation, it became

apparent that only a very small number of the 11,500 covered entities

used in-house pharmacies (approximately 500), although additional

entities participated by buying drugs for their physician dispensing

activities. In addition, many of the larger groups of covered entities,

including community and migrant health centers, hemophilia clinics and

most of the Ryan White HIV service programs (e.g., State AIDS Drug

Assistance Programs) depend upon outside pharmacy services. Yet,

because the delivery of pharmacy services is central to the mission of

(and a legal mandate in some instances for) these providers, they rely

on outside pharmacies to fill the need. It would defeat the purpose of

the 340B program if these covered entities could not use their

affiliated pharmacies in order to participate in the 340B program.

Otherwise, they would be faced with the untenable dilemma of having

either to expend precious resources to develop their own in-house

pharmacies (which for many would be impossible) or forego participation

in the program altogether. Neither option is within the interest of the

covered entities, the patients they serve, or is consistent with the

intent of the law.

As early as 1993, several covered entity groups and a home care

company came forward to assist the Department in developing a workable

mechanism to use outside pharmacies under arrangements which would

decrease the drug diversion potential. The result was the November 1

proposed notice, which articulates a voluntary model agreement.

Currently, contract pharmacies are used by a number of large

organizations, such as the American Red Cross, several community health

centers, and the New York Blood Consortium.

It must be understood that the use of contract services is only

providing those covered entities (which would otherwise be unable to

participate in the program) a process for accessing 340B pricing. The

mechanism does not in any way extend this pricing to entities which do

not meet program eligibility. However, it has permitted more eligible

entities to participate in the program with a reasonable assurance that

the potential for drug diversion is eliminated.

Comment: The guidelines were proposed without a comprehensive

notice and comment period.

Response: During the early months following enactment, it became

clear that there were many gaps in the legislation and some form of

program structure was necessary to move the program forward. There were

approximately 11,500 eligible entities, 500 participating

manufacturers, numerous wholesalers and many Federal programs affected

by this legislation and all seeking guidance. It was incumbent upon the

Department to implement this difficult Congressional mandate in an

expeditious manner.

Interpretive rules and statements of policy were developed to

provide necessary program guidance. The Department has published these

guidelines in the Federal Register, used a Federal clearance process

(including the Office of Management and Budget's clearance) and

provided a public comment period to obtain both Federal as well as

public input into guideline development. The Department considered all

comments in developing these final guidelines.

The guidelines explain how the Department intends to administer the

340B, further explain the statutory language by clarifying the meaning

given by the Department to particular words or phrases, and do not

exceed the purpose of 340B or conflict with any of its provisions. We

believe that these guidelines create no new law and create no new

rights or duties; therefore, they are not subject to the Administrative

Procedure Act's requirement of notice and comment. Nevertheless, the

Department chose to solicit and respond to public comment.

Comment: As a matter of State law, entities possess the right to

hire retail pharmacies to act as their agents in providing

pharmaceutical care to their patients. As a general rule, a person or

entity privileged to perform an act may appoint an agent to perform the

act unless contrary to public policy or an agreement requiring personal

performance. Restatement of Agency 2d Sec. 17 (1995). Hence, even in

the absence of Federal guidelines, covered entities have the right to

contract with retail pharmacies for the purpose of dispensing 340B

drugs. By issuing guidelines in this area, ODP is not seeking to create

a new right but rather is simply recognizing an existing right that

covered entities enjoy under State law.

Response: We agree. However, entities, under any distribution

system, must comply with the statutory prohibition against diversion of

340B drugs to individuals who are not patients of the covered entities.

Further, the dispensing of drugs, purchased with a 340B discount, must

not result in the generation of a Medicaid rebate.

Comment: Participation in the contract pharmacy mechanism by

hemophilia treatment centers funded under the Maternal and Child Health

Block Grant Program would contravene the central goals of that program

and could result in grant termination or non-renewal.

Response: Block grant funds are designed for formula allocation to

the States to meet specific defined needs in the legislation. Congress

recognized that the Maternal and Child Health Bureau (MCHB) had other

needs that should be met more flexibly; therefore, fifteen percent of

the appropriation is a discretionary set-aside. These funds are not

subject to the specific parameters of block grant funds but instead are

used to fulfill other goals within the MCHB mission. This includes the

provision of services (including pharmaceuticals) to individuals with

hemophilia disorders and their families. Therefore, the purchase of

pharmaceuticals by hemophilia centers does not contravene grant

principles.

Comment: The contract pharmacy mechanism contravenes Federal and

State laws and regulations (e.g., Prescription Drug Marketing Act and

the Anti-kickback Statute).

Response: We found no indication that the guidelines contravene

Federal or State law. Regarding allegations that the guidelines

contravene the Prescription Drug Marketing Act (PDMA), it is clear that

the guidelines fall squarely within the PDMA resale exception that

allows the dispensing of a prescription drug purchased by a health care

entity when dispensing is pursuant to a prescription. See 21 U.S.C.

353(c)(3)(B)(v). Under the guidelines, the contract pharmacy would

dispense 340B drugs to patients of the covered entity pursuant to a

prescription. The contract pharmacy would act as an agent of the

covered entity, in that it would not resell a prescription drug but

rather distribute the drug on behalf of the covered entity. This

situation is akin to a covered entity having its own pharmacy.

Moreover, the guidelines include controls intended to prevent diversion

and provide for accountability of drug stocks. For these reasons, the

guidelines are consistent with both the letter and the spirit of the

PDMA.

We believe it necessary to ensure that covered entities contracting

with pharmacies to dispense 340B drugs are aware of the requirements of

the Federal anti-kickback statute and the way in

[[Page 43551]]

which such requirements could apply to their arrangements with

contracting pharmacies. To this end, we inserted into the guidelines a

discussion of the statute's requirements and its potential application

in this type of contracting situation.

In addition, provision (e) of the guidelines provides that the

``contractor and the covered entity will adhere to all Federal, State,

and local laws and requirements.'' As a general matter, we found it

impossible to discuss each State's laws and regulations regarding drug

purchase, distribution, and dispensing in relation to the many

different types of entities and their individual needs. We believe it

appropriate that the guidelines include a provision that requires each

entity and contractor to be responsible for ensuring that their

particular contracting arrangements and operations conform to the

requirements of all applicable laws and regulations.

Comment: The ODP should develop a uniform contractual agreement and

distribute this agreement to covered entities for use without

modification.

Response: The guidelines propose a model format only. The

Department has included in the guidelines provisions necessary to

ensure that covered entities and contract pharmacies understand and

agree not to violate 340B provisions. Because of the wide diversity of

covered entities (including hemophilia clinics, large hospitals,

migrant health clinics, family planning service programs and State AIDS

drug assistance programs), it would be impossible to include provisions

responsive to the needs of all entities.

Comment: ODP should keep a list of all acceptable contract

pharmacies.

Response: Any pharmacy licensed by a State Board of Pharmacy is

acceptable.

Comment: Some State laws require that manufacturers ensure that a

buyer is licensed to purchase pharmaceuticals. Covered entities that do

not have pharmacy operations would not be licensed, and thus, in some

States, manufacturers could not receive from the covered entity the

assurance required by State law.

Response: Provision (e) provides that the covered entity will

adhere to all Federal, State and local laws and requirements.

Accordingly, if State X requires an entity to be licensed to purchase

drugs and a covered entity subject to the laws of State X does not have

a pharmacy license, it may not be able to purchase drugs. However, if

State X permits a covered entity to use contract pharmacy services to

purchase drugs on its behalf, the entity could presumably use this

mechanism. To the extent the guidelines may be inconsistent with a

State's distributor licensing requirements, this same reasoning would

apply.

Comment: Covered entities may bill insurers for 340B drugs at the

usual price, resulting in the savings not being passed on to the

patients.

Response: Section 340B does not limit the pricing behavior of

covered entities. It is our understanding that covered entities have a

variety of drug pricing approaches. While some may pass all or a

significant part of the discount to their patients, others may set the

price slightly higher than the actual acquisition cost plus a

reasonable dispensing fee, using the savings to reach more eligible

patients and provide more comprehensive services. The Department

intends to examine the section 340B drug pricing activities of covered

entities to determine the various approaches used and the rationale for

these approaches. However, until it completes its examination of this

issue, the Department notes that a modest section 340B price markup,

with saving realized from the discounts used by covered entities only

for purposes of the federal program (including certain disproportionate

share hospitals) which provides its section 340B eligibility does not

appear to be inconsistent with the drug pricing program.

Comment: There should be a limitation to only those covered

entities that do not have the capability under State pharmacy law to

purchase and dispense prescription drugs.

Response: The guidelines have been revised to read that the

``mechanism is designed to facilitate program participation for those

eligible covered entities that do not have access to an appropriate

`in-house' pharmacy services.'' However, this is not a bar to the use

of the mechanism by any covered entity.

Comment: A covered entity should use only one form of

participation, and if it purchases in its own right for some patients,

it should not use a contractor for others.

Response: Some covered entities may receive nominal pricing

directly from a manufacturer (e.g., family planning) for specific

drugs, may obtain certain drugs through promotional discounts, or have

a manufacturer-specific indigent free drug program which could

necessitate the procurement of other pharmaceuticals from a retail

pharmacy. The statute does not limit the covered entities' access to

these avenues of drug purchasing.

Comment: The Department should establish criteria that a contractor

and a covered entity must meet in order to be in compliance with

section 340B provisions and receive 340B pricing.

Response: The contracted pharmacy mechanism does establish these

criteria in that it includes provisions for purchasing only by the

entity and not contractor, identifies customary and adequate records

that can provide an audit trail, preclusion of the filling of Medicaid

prescriptions (thus preventing duplicate discounting), and three

provisions related to the potential for drug diversion (agreement not

to divert with specified penalties, customary drug tracking systems,

and an agreement to permit manufacturer and HHS audits).

Comment: The reference to ``facility'' in provision (b) should be

changed to ``entity'' for clarification.

Response: The guidelines were revised accordingly.

Comment: The Department should review all contracts between covered

entities and pharmacies or develop a procedure for certifying that each

contract pharmacy arrangement meets the mechanism criteria.

Response: The Department has added a provision to the guidelines

which suggests that covered entities utilizing contract pharmacy

services submit to the ODP a certification that they have signed and

have in effect an agreement with the pharmacy contractor containing

provisions (a) through (k) as outlined in the guidelines. For the

convenience of participating drug manufacturers, the names of covered

entities which submit a certification, or have submitted an alternate

mechanism to reduce the potential for drug diversion which has been

approved by ODP, will be placed on the program electronic bulletin

board (EDRS) for public access.

Comment: Covered entities should be permitted to contract with more

than one site and contractor. Although we understand that the

limitation of one contractor (with multiple sites) was intended to

address drug diversion concerns, covered entities will have the

incentive of directing their patients to the contract pharmacy site

participating in the program, even though there may be several

nonparticipating sites of contractors that would be more convenient for

the patients.

Response: Covered entities are unlikely to select a contract

pharmacy that is not convenient for their patients. See also the

discussion of patient choice, below.

Comment: PHS is moving from a direct purchase discount program to

an indirect charge-back contracting system.

[[Page 43552]]

Response: All 340B drugs will be sold to covered entities;

therefore, there are no additional charge backs involved.

(2) Patient Choice

Comment: Provision (c) provides that the patient may obtain the

prescription from the pharmacy provider of his or her choice. Pharmacy

providers cannot provide prescriptions, as only a physician can write a

prescription. The guidelines should permit the patient to obtain the

prescription from the covered entity physician and then be able to fill

that prescription at the pharmacy of his or her choice. Further, the

covered entity physician should inform each patient that he or she has

the freedom to choose any pharmacy to fill the prescription.

Response: The use of the word ``prescription'' may be somewhat

confusing. We have revised this provision to read ``may obtain the

prescription from the covered entity and then obtain the drug(s) from

the pharmacy provider of his or her choice.'' In addition, a provision

is added to address the responsibility of the covered entity physician

to inform the patient of his or her freedom of choice.

Comment: Wording should be added to provision (c) to make it clear

that when a patient obtains a drug from a retail pharmacy other than

the entity's contract pharmacy, the manufacturer does not have to offer

this drug at 340B pricing.

Response: The guidelines were revised accordingly.

(3) Bill to/Ship to

Comment: The type of ``bill to, ship to'' arrangement proposed in

the notice is not a ``purchase'' by the covered entity.

Response: Please note provision (a) of the notice which states

``the covered entity will purchase the drug.'' The contract pharmacy

does not purchase the drug. Title to the drugs passes to the covered

entity.

Comment: A ``ship to, bill to'' arrangement may not be lawful in

many States (e.g., state distributor licensing requirements).

Response: The Department obtained information from both the

American Pharmaceutical Association and the National Association of

Boards of Pharmacy which suggests that no State would consider this

type of activity unlawful.

Comment: If the ``ship to, bill to'' procedure is implemented

through wholesalers, there are no procedures in place that can enable a

manufacturer to conduct an adequate audit.

Response: The guidelines provide that the covered entity will

verify, using the contractor's (readily retrievable) customary business

records, that a tracking system exists which will ensure that drugs

purchased under the Act are not diverted to individuals who are not

patients of the covered entity. These records will be maintained for

the period of time required by the State law and regulations. The

guidelines provide that the contractor will provide the covered entity

with reports consistent with normal business practices as well as

maintain records separate from it's own operation. In addition, the

contractor will agree to be subject to audits by both the manufacturers

and the Department. In light of these provisions, audits will be

possible, regardless of whether drugs are shipped by manufacturers or

wholesalers.

Comment: A ``ship to, bill to'' procedure could interfere with

marketing arrangements that an individual manufacturer may have

established as part of its usual business practices.

Response: Because the manufacturer is still selling to the covered

entities, we can see no interference with marketing arrangements. The

manufacturer will be using its usual business practices. Only the

delivery of the drug will be altered.

Comment: The covered entity (not its contractor) will place all

orders for drugs based upon its projections of the needs of its

patients.

Response: Because the covered entity will have no knowledge of the

inventory levels of the pharmacy, it would be unrealistic to include a

provision that the covered entity will order 340B drugs.

Comment: The covered entity, consistent with customary business

practices in wholesale purchases, should make timely payment of

invoices for drugs shipped to the contractor pursuant to the entity's

order.

Response: We have included this concept in the guidelines, Section

1 of Appendix.

(4) Penalties

Comment: The penalty for the contract pharmacy which violates the

agreement not to resell or transfer a drug purchased at 340B pricing is

inadequate. Knowing violators should be fined beyond their unjust

profit and criminal and fraud penalties should be imposed.

Response: The Department has no statutory authority to assess

additional penalties beyond the authority provided in section 340B.

However, to the extent the Department is aware that improper action by

an entity or a contract pharmacy may be a violation of law, we will

refer such cases to appropriate authorities.

(5) Potential Drug Diversion

Comment: PHS should conduct an annual audit of each contract

pharmacy to ensure compliance with all Departmental rules and

regulations.

Response: Subject to the availability of funds, the Department

intends to conduct a study of the contract pharmacy mechanism.

Depending upon the results of this analysis and the availability of

funds, further study may result. Annual audits of each contract

pharmacy situation would be burdensome and are not feasible.

Comment: Contract pharmacies will be motivated to identify patients

other than those of the covered entity whose drug usage can afford the

contractor a profit opportunity. The covered entity should be

responsible to the manufacturer for any diversion by the contractor of

340B drugs to individuals who are not patients of the covered entity.

Response: The guidelines contains provision (h), in which both

parties agree to not ``resell or transfer a drug purchased at section

340B prices to an individual who is not a patient of the covered

entity.'' In addition, this provision provides that if diversion has

occurred, the contractor will pay the amount of the discount in

question so that the covered entity can reimburse the manufacturer, as

required by section 340B(a)(5)(D).

Comment: The mechanism should include provisions for ensuring that

the agreement will, in fact, be enforced.

Response: The Department does have the authority to remove a

covered entity from the eligibility list if it (or its contract

pharmacy) is found to have diverted 340B drugs to individuals who are

not patients of the entity. To this end, the Department has developed a

mechanism to receive and investigate complaints concerning drug

diversion. This mechanism was published in the Federal Register for

notice and comment on June 10, 1994 (59 FR 30021). In addition, the

Department, at various public meetings concerning the implementation of

340B, has requested documentation of any covered entity drug diversion.

To date, the Department has received no indication of drug diversion in

relation to drugs purchased at 340B discount pricing that has required

an official Departmental investigation.

Comment: The manufacturer appears to bear the sole risk arising

from abuses of the program and has no recourse if such abuse occurs.

The manufacturer

[[Page 43553]]

has limited ability to verify an arrangement between the covered entity

and the contract pharmacy. Under the statute, the manufacturer's only

remedy is to demand an audit; however, the lack of final audit

guidelines has effectively prevented manufacturers from undertaking

this type of activity. PHS should make arrangements for injunctive

relief to prevent damages from ongoing violations of the statute, or

provisions for terminating the participation of covered entities or

their contractors.

Response: The manufacturer has sufficient remedies available to

detect and eliminate abuse of the program. First, the manufacturer may

audit the entity. Although the audit guidelines were not published in

final form, we consider the proposed guidelines, published in the

Federal Register, a sufficient statement of Department guidelines to

allow manufacturers to proceed with an entity audit. Second, the

Department has developed a dispute resolution process to provide

parties with an informal mechanism to bring before the Department

allegations of behavior that is in violation of 340B. Third, the

contract pharmacy guidelines provide that if the covered entity or its

contractor is found to have violated the 340B prohibition against drug

diversion (and duplicate discounting), the covered entity could be

removed from the list of covered entities and could no longer access

340B pricing.

Comment: The covered entity should establish a process for a

quarterly reconciliation of its prescribing records with the

contractor's inventory and dispensing records to provide for early

detection of diversion and remediation of irregularities.

Response: We have included a provision that covered entity will

establish a process for a quarterly random (sample) comparison of its

prescribing records with the contractor's dispensing records to detect

potential irregularities.

Comment: The covered entity should establish prior authorization

protocol, assuring that the individual's status as a patient of the

entity is confirmed by the entity in advance of product dispensing.

Response: The contractor should have some type of assurance that

the patient to whom the contractor is dispensing the 340B drug is a

patient of a covered entity participating in the 340B Program. To that

end, we have added a provision to the guidelines stating that the

covered entity and the contractor will develop a system to verify

patient eligibility (e.g., eligible patient list or a validated

prescription). Additionally, we have included a suggested contract

provision which states, ``(pharmacy) will dispense covered drugs only

in the following circumstances: (1) Upon presentation of a prescription

bearing the (covered entity's) name, the eligible patient's name, a

designation that the patient is an eligible patient, and the signature

of a legally qualified health care provider affiliated with the

(covered entity); or (2) receipt of a prescription ordered by telephone

on behalf of an eligible patient by a legally qualified health care

provider affiliated with the (covered entity) who states that the

prescription is for an eligible patient. The (covered entity) should

provide a list to the (pharmacy) of all such qualified health care

providers and will update the list of providers to reflect any changes,

which is consistent with customary business practice.''

Comment: The contract agreement should restrict pharmacy services

to only those patients who receive their medical care from the covered

entity.

Response: Provision (g) of the guidelines provides that the

contractor will not resell or transfer a 340B drug to an individual who

is not a patient of the entity. The Department issued proposed

guidelines to define the word ``patient'' in a Federal Register notice

on August 3, 1995. See 60 FR 39762. Provision (2) of the definition

provides that an individual is a patient of a covered entity if, among

other requirements, the ``individual receives health care services from

a health care professional who is either employed by the covered entity

or provides health care under contractual or other arrangements (e.g.,

referral for consultation) such that the responsibility for the care

provided remains with the covered entity.'' Currently, the Department

is analyzing the comments received in response to that notice and is

developing final guidelines.

It must be noted that the covered entity is responsible for any

diversion of its drugs to ineligible individuals; therefore, it must

make every effort to thoroughly scrutinize the contractor's dispensing

records, to determine if the 340B drugs were dispensed to only eligible

recipients. If a manufacturer believes that a covered entity contractor

is diverting 340B drugs to ineligible recipients, the manufacturer

should immediately contact the Department with this information and

submit all supporting documentation so that a thorough investigation

can be initiated.

Comment: PHS should oversee contractors' compliance with the

contracts regarding the 340B prohibition against drug diversion and

duplicate discounting.

Response: Because the covered entity purchases the drug, retaining

title, and directs shipment to its contractor, it retains

responsibility for the drug. If the drug generates a Medicaid rebate or

is diverted to an individual who is not a patient of the covered

entity, the entity will be responsible for such activity. The

Department and a participating manufacturer have the authority to audit

the records of the covered entity and the contractor that directly

relate to that manufacturer's drugs and to the 340B prohibitions

against drug diversion and duplicate discounting. See proposed Audit

Guidelines, 59 FR 30021, June 10, 1994. Further, the Department has

proposed a dispute resolution process in which a manufacturer may bring

a claim against an entity for drug diversion or duplicate discounting.

See Dispute Resolution, 59 FR 30023. If the entity (or its contractor)

is found to have violated such prohibitions, the entity is required by

340B(a)(5)(D) to pay the manufacturer the amount of the discount in

dispute, and, pursuant to 340B(a)(4), the Department may determine that

the entity is no longer a ``covered entity'' eligible to access 340B

pricing.

We have added several suggested contract provisions that are

consistent with normal business practices to the guidelines (Appendix)

to provide further technical assistance in this area. One provision

concerning potential discrepancies in ordering and shipping states,

``the pharmacy will compare all shipments received to the orders and

inform the covered entity of any discrepancy within five (5) business

days of receipt.'' Concerning an appropriate tracking system to prevent

drug diversion, another provision states, ``prior to the pharmacy

providing pharmacy services pursuant to this agreement, the (covered

entity) will have the opportunity, upon reasonable notice and during

business hours, to examine the tracking system and may require (the

pharmacy) to make any modifications to such system as the (covered

entity) may, in its sole discretion, require. Such a system may include

sample quarterly comparisons of eligible patient prescriptions to the

dispensing records and a six (6) month comparison of 340B drug

purchasing and dispensing records. The (pharmacy) will permit the

(covered entity) or its duly authorized representatives to have

reasonable access to (pharmacy's) facilities and records during the

term of this agreement in order to make periodic checks regarding the

efficacy of such tracking systems. (Pharmacy) agrees to

[[Page 43554]]

make any and all adjustments to the tracking system which (covered

entity) advises are reasonably necessary to prevent diversion of

covered drugs to individuals who are not patients of the (covered

entity).''

Comment: There should be a process for excluding from the 340B

Program those contractors that are in violation of the statute and the

guidelines should explicitly note that the pharmacy contractor will be

subject to additional civil or criminal penalties if violation of the

guideline involves a violation of State or Federal law.

Response: Covered entities which are found to have violated the

prohibitions of section 340B(a)(5) can be excluded from the 340B

Program, after an appropriate opportunity to be heard. See Dispute

Resolution Guidelines in 59 FR 30023, June 10, 1994. However, if the

program finds that the pharmacy contractor has violated these statutory

prohibitions, it cannot bar this pharmacy from dispensing 340B drugs

for a covered entity. Nevertheless, the program intends to alert any

entity which submits a certification with this particular pharmacy

listed as the contractor as to this pharmacy's past activities. If the

covered entity insists upon using this pharmacy, the Department will

carefully scrutinize its activities. An additional provision was added

to address the potential for civil or criminal penalties if the

contractor violates Federal or State law.

Comment: The agreement should appoint the pharmacy contractor to be

the agent of the covered entity and discuss the duties to be performed

by the agent on behalf of the covered entity and the agent's rights.

Response: We believe that the relationship between the covered

entity and the contract pharmacy is one of agency. However, the form of

the relationship will be dictated by the terms of the contract;

therefore, it is not essential to characterize the relationship as

meeting or not meeting the standards which would serve under applicable

law to establish an agency relationship. The contract terms address the

relative duties of the parties in relation to section 340B and

diversion and duplicate discount concerns that have been raised by the

commenters. Accordingly, we have concluded that it is unnecessary to

label the relationship between the covered entity and the contract

pharmacy.

Comment: The contract pharmacy is fully accountable for maintaining

the security of the PHS inventory.

Response: There is no requirement for a separate (physical)

inventory for drugs purchased at a 340B discount, because a separate

data system will be used to verify appropriate dispensing.

Comment: Contract pharmacies are most likely Medicaid pharmacy

providers, while the covered entity likely is not. Because State

Medicaid programs are unlikely to issue pharmacy numbers to anyone

other than licensed pharmacies, covered entities that are not licensed

pharmacies will not be able to bill Medicaid for prescriptions

dispensed by the contract pharmacies. This task will be completed by

the contract pharmacy. The mechanism excludes Medicaid drugs;

therefore, the contract pharmacy must have two Medicaid numbers (i.e.,

340B exclusion package and one to bill Medicaid for its regular

customers). However, PHS has not required the contract pharmacy to do

so. Moreover, neither the pharmacy nor the State has any incentive to

``make arrangements'' to carry out the statute, since both may gain

from inadequate enforcement.

Response: The mechanism requires the parties to comply with the

prohibition on filling Medicaid prescriptions with drugs purchased at

340B pricing. Neither the covered entity nor the contract pharmacy will

bill Medicaid for 340B drug reimbursement; therefore, there will be no

need for two Medicaid numbers. The 340B drugs will not generate

Medicaid rebates.

Comment: As the owner of the drug, the covered entity should be

responsible for establishing the price for each drug sold to a patient

of the entity (effectively preventing the contractor from charging

whatever price it chooses) and assuming full responsibility for such

prices under the terms of the PHS grant and any applicable consumer

protection laws.

Response: Even though it is clearly stated in the guidelines that

the covered entity must purchase the drug (not the contractor), which

would give to the covered entity title to and responsibility for the

drug, we have added the following clarifying language to provision (a):

``* * * will purchase the drug and will assume full responsibility for

establishing its price, pursuant to terms of a PHS grant (if

applicable) and any applicable consumer protection laws.''

(6) Records

Comment: The contractor should assure that all pertinent

reimbursement accounts and dispensing records maintained by the

contractor for the covered entity are separate from the contractor's

own operations and are accessible to the covered entity, PHS, and the

manufacturers in the event of an audit. The contractor should provide

these records to the manufacturer upon request.

Response: We have added the concept of separate records to

provision (j) to assure the availability of these records in the case

of an audit by the manufacturer. However, a manufacturer has statutory

authority to access these entity records by performing an audit;

therefore, to require the entity to submit records upon demand would be

unduly burdensome.

Comment: ODP should establish standards for reporting that will

ensure consistency of the information and approve whatever ``record-

keeping'' system is used.

Response: Any reasonable system which will provide an adequate

audit trail will be acceptable. However, reporting should be consistent

with State pharmacy laws and other reporting mechanisms. As stated

earlier in this section, sample contract provisions are suggested which

describe such records and reports (e.g., prescription files, velocity

reports, and records of ordering and receipt).

Comment: Reporting requirements should include some record or

report that assures that only patients of the covered entity were

served.

Response: Provision (f) provides that the contractor will provide

the covered entity with reports as deemed appropriate using normal and

customary business records.

Comment: The agreement should require that the pharmacy contractor

maintain separate inventories and separate records for patients of the

PHS entity contracting for pharmacy services.

Response: The guidelines have been changed to include a provision

for separate dispensing records for patients of the covered entity.

However, the requirement for a separate inventory of 340B drugs is

unnecessary, because the covered entity is required to monitor

dispensing and inventory records. In addition, these records are also

subject to Department and manufacturer audits. A separate inventory is

a wasteful concept with respect to time, space and money. Further, it

provides little if any additional security, as a separate inventory

only speaks to what is currently on the shelf and not what should be on

the shelf. On the other hand, dispensing and other records will

accurately indicate use of 340B drugs.

Comment: The covered entity is responsible for making arrangements

to seek reimbursement from third parties for 340B drugs used in

treating patients of the entity. If the covered entity receives a PHS

grant, it would lose its

[[Page 43555]]

grant eligibility for failing to make appropriate arrangements.

Response: Since the entity purchases the drugs, it has the option

of seeking reimbursement from third parties itself or contracting for

this service. However, to the extent that a covered entity (or its

contract pharmacy acting on its behalf) fails to comply with grant

conditions, the entity may be subject to grant penalties.

Comment: To the extent that the covered entity makes arrangements

for the pharmacy contractor to submit claims for third party

reimbursement, the covered entity should assume full responsibility

under State consumer protection laws, insurance, fraud, and State and

Federal health care laws with respect to any false claims charges or

allegations of consumer or insurance fraud.

Response: The ODP is not authorized to enforce or interpret such

laws. If we become aware of possible violations of such laws, we will

refer these cases to appropriate authorities.

(C) Contract Pharmacy Services Revised Final Mechanism

Covered entities that wish to utilize contract pharmacy services to

dispense section 340B outpatient drugs are encouraged to sign and have

in effect a contract pharmacy service agreement between the covered

entity and the pharmacy. This mechanism is designed to facilitate

program participation for those eligible covered entities that do not

have access to appropriate ``in-house'' pharmacy services. See Appendix

for suggested contract provisions.

(1) The following is a suggested model agreement format:

(a) The covered entity will purchase the drug and assume

responsibility for establishing its price, pursuant to the terms of

a PHS grant (if applicable) and any applicable consumer protection

laws.

A ``ship to, bill to'' procedure may be used in which the

covered entity purchases the drug, the manufacturer bills the entity

for the drug that it purchased, but ships the drug directly to the

contract pharmacy. See section 1 of Appendix.

(b) The contractor will provide all pharmacy services (e.g.,

dispensing, record keeping, drug utilization review, formulary

maintenance, patient profile, counseling). Each covered entity which

purchases its covered outpatient drugs has the option of

individually contracting for pharmacy services with the pharmacy of

its choice. The limitation of one pharmacy contractor per entity

does not preclude the selection of a pharmacy contractor with

multiple pharmacy sites, as long as only one site is used for the

contracted services. [The ODP will be evaluating the feasibility of

permitting these covered entities to contract with more than one

site and contractor.]

(c) The covered entity health care provider will inform the

patient of his or her freedom to choose a pharmacy provider. If the

patient does not elect to use the contracted service, the patient

may obtain the prescription from the covered entity and then obtain

the drug(s) from the pharmacy provider of his or her choice.

When a patient obtains a drug from a retail pharmacy other than

the entity contract pharmacy, the manufacturer is not required to

offer this drug at 340B pricing.

(d) The contractor may provide the covered entity services,

other than pharmacy, at the option of the covered entity (e.g., home

care, reimbursement services). Regardless of the services provided

by the contractor, access to 340B pricing will always be restricted

to only patients of the covered entity.

(e) The contractor and the covered entity will adhere to all

Federal, State, and local laws and requirements. Additionally, all

PHS grantees will adhere to all rules and regulations established by

the grant funding office.

Both the covered entity and the contract pharmacy are aware of

the potential for civil or criminal penalties if the covered entity

and/or the contract pharmacy violate Federal or State law. [The

Department reserves the right to take such action as may be

appropriate if it determines that such a violation has occurred.]

(f) The contractor will provide the covered entity with reports

consistent with customary business practices (e.g., quarterly

billing statements, status reports of collections and receiving and

dispensing records). See Section 2 of Appendix.

(g) The contractor, with the assistance of the covered entity,

will establish and maintain a tracking system suitable to prevent

diversion of section 340B discounted drugs to individuals who are

not patients of the covered entity. Customary business records may

be used for this purpose. The covered entity will establish a

process for a periodic random (sample) comparison of its prescribing

records with the contractor's dispensing records to detect potential

irregularities. See Section 3 of Appendix.

(h) The covered entity and the contract pharmacy will develop a

system to verify patient eligibility. [The Department's draft

guidance defining covered entity ``patient'' is set forth in an

August 3, l995, Federal Register notice. See 60 FR 39762.]

Both parties agree that they will not resell or transfer a drug

purchased at section 340B pricing to an individual who is not a

patient of the covered entity. See section 340B(a)(5)(B). The

covered entity understands that it can be removed from the list of

covered entities because of its participation in drug diversion, a

340B(a)(5) prohibition, and no longer be eligible for 340B pricing.

See Section 4 of Appendix.

(i) Both parties will not use drugs purchased under section 340B

to dispense Medicaid prescriptions, unless the contract pharmacy and

the State Medicaid agency have established an arrangement to prevent

duplicate discounting.

(j) Both parties understand that they are subject to audits (by

the Department and participating manufacturers) of records that

directly pertain to the entity's compliance with the drug resale or

transfer prohibition and the prohibition against duplicate Medicaid

rebates and 340B discounts. See section 340B(a)(5).

The contractor will assure that all pertinent reimbursement

accounts and dispensing records, maintained by the contractor, will

be separate from the contractor's own operations and will be

accessible to the covered entity, the Department, and the

manufacturer in the case of a manufacturer audit.

(k) Upon request, a copy of this contract pharmacy service

agreement will be provided to a participating manufacturer which

sells covered outpatient drugs to the covered entity. All

confidential propriety information may be deleted from the document.

(2) Certification

Under section 340B, we believe that if a covered entity using

contract pharmacy services requests to purchase a covered drug from a

participating manufacturer, the statute directs the manufacturer to

sell the drug at the discounted price. If the entity directs the drug

shipment to its contract pharmacy, we see no basis on which to conclude

that section 340B precludes this type of transaction or otherwise

exempts the manufacturer from statutory compliance. However, the entity

must comply, under any distribution mechanism, with the statutory

prohibition on drug diversion and duplicating discounting.

To provide ODP and manufacturers with assurance that the covered

entity has acted in a manner which limits the potential for drug

diversion, the covered entity is encouraged to submit to ODP a

certification that it has signed and has in effect an agreement with

the contract pharmacy containing the aforementioned provisions.

However, ODP will review any alternative mechanism which is designed to

reduce the potential for drug diversion. The names of those covered

entities which submit a certification, or an alternate mechanism

approved by ODP, will be placed on the EDRS for the convenience of

participating drug manufacturers.

(3) Anti-kickback Statute

Contractors and covered entities must be aware of the potential for

civil or criminal penalties if the contractor violates Federal or State

law. In negotiating and executing a contracted pharmacy service

agreement pursuant to these guidelines, contractors and covered

entities should be aware of and take into consideration the provisions

of the Medicare and Medicaid anti-kickback statute, 42 U.S.C. 1320a-

7b(b). This statute makes it a felony for a person or entity to

knowingly and willfully offer, pay, solicit, or receive

[[Page 43556]]

remuneration with the intent to induce, or in return for the referral

of, Medicare or a State health care program business. State health care

programs are Medicaid, the Maternal and Child Health Block Grant

program, and the Social Services Block Grant program. Apart from the

criminal penalties, a person or entity is also subject to exclusion

from participation in the Medicare and State health care programs for a

knowing and willful violation of the statute pursuant to 42 U.S.C.

1320a-7(b)(7).

The anti-kickback statute is very broad. Prohibited conduct covers

not only remuneration intended to induce referrals of patients, but

also includes remuneration intended to induce the purchasing, leasing,

ordering, or arranging for any good, facility, service, or item paid

for by Medicare or a State health care program. The statute

specifically identifies kickbacks, bribes, and rebates as illegal

remuneration, but also covers the transferring of anything of value in

any form or manner whatsoever. This illegal remuneration may be

furnished directly or indirectly, overtly or covertly, in cash or in

kind and covers situations where there is no direct payment at all, but

merely a discount or other reduction in price or the offering of a free

good(s).

Arrangements between contractors and covered entities that could

violate the anti-kickback statute would include any situation where the

covered entity agrees to refer patients to the contractor in return for

the contractor agreeing to undertake or furnish certain activities or

services to the covered entity at no charge or at a reduced or below

cost charge. These activities or services would include the provision

of contracted pharmacy services, home care services, money or grants

for staff or service support, or medical equipment or supplies, and the

remodeling of the covered entity's premises. For example, if a

contractor agreed to furnish covered outpatient drugs in return for the

covered entity referring its Medicaid patients to the contractor to

have their prescriptions filled, the arrangement would violate the

anti-kickback statute. Similarly, if the contractor agreed to provide

billing services for the covered entity at no charge in return for the

covered entity referring its patients to the contractor for home or

durable medical equipment, the statute would be violated.

Pursuant to the authority in 42 U.S.C. 1320a-7b(b)(3), the

Secretary of HHS has published regulations setting forth certain

exceptions to the anti-kickback statute, commonly referred to as ``safe

harbors.'' These regulations are codified at 42 CFR 1001.952. Each of

the safe harbors sets forth various requirements which may be met in

order for a person or entity to be immune from prosecution or

exclusion.

(D) Appendix--Suggested Contract Provisions

(1) ``The covered entity will order covered drugs directly from the

manufacturer, from a designated sales representative, or a drug

wholesaler and arrange to be billed directly for such drugs. The

covered entity will arrange for shipment of such drugs directly to the

pharmacy. The pharmacy will compare all shipments received to the

orders and inform the covered entity of any discrepancy within five (5)

business days of receipt. The covered entity will make timely payments

for such drugs delivered to the (pharmacy) pursuant to the entity's

order.''

(2) ``The covered entity will verify, using the contractor's

(readily retrievable) customary business records, that a tracking

system exists which will ensure that drugs purchased under the Act are

not diverted to individuals who are not patients of the covered entity.

Such records can include: prescription files, velocity reports, and

records of ordering and receipt. These records will be maintained for

the period of time required by State law and regulations.''

(3) ``Prior to the pharmacy providing pharmacy services pursuant to

this agreement, the covered entity will have the opportunity, upon

reasonable notice and during business hours, to examine the tracking

system. For example, such a tracking system may include quarterly

sample comparisons of eligible patient prescriptions to the dispensing

records and a six (6) month comparison of 340B drug purchasing and

dispensing records as is routinely done in other reconciliation

procedures. The pharmacy will permit the covered entity or its duly

authorized representatives to have reasonable access to pharmacy's

facilities and records during the term of this agreement in order to

make periodic checks regarding the efficacy of such tracking systems.

The pharmacy agrees to make any and all adjustments to the tracking

system which covered entity advises are reasonably necessary to prevent

diversion of covered drugs to individuals who are not patients of the

covered entity.''

(4) ``The pharmacy will dispense covered drugs only in the

following circumstances: (a) Upon presentation of a prescription

bearing the covered entity's name, the eligible patient's name, a

designation that the patient is an eligible patient, and the signature

of a legally qualified health care provider affiliated with the covered

entity; or (b) receipt of a prescription ordered by telephone on behalf

of an eligible patient by a legally qualified health care provider

affiliated with the covered entity who states that the prescription is

for an eligible patient. The covered entity will furnish a list to the

pharmacy of all such qualified health care providers and will update

the list of providers to reflect any changes. If a contract pharmacy is

found to have violated the drug diversion prohibition, the pharmacy

will pay the entity the amount of the discount in question so that the

entity can reimburse the manufacturer.''

Dated: August 14, 1996.

Thomas G. Morford,

Acting Administrator, Health Resources and Services Administration.

[FR Doc. 96-21485 Filed 8-22-96; 8:45 am]

BILLING CODE 4160-15-P

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.